AU2006216683A1 - Compositions and methods for classifying biological samples - Google Patents

Compositions and methods for classifying biological samples Download PDF

Info

Publication number
AU2006216683A1
AU2006216683A1 AU2006216683A AU2006216683A AU2006216683A1 AU 2006216683 A1 AU2006216683 A1 AU 2006216683A1 AU 2006216683 A AU2006216683 A AU 2006216683A AU 2006216683 A AU2006216683 A AU 2006216683A AU 2006216683 A1 AU2006216683 A1 AU 2006216683A1
Authority
AU
Australia
Prior art keywords
epitopes
class
sample
samples
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006216683A
Other languages
English (en)
Inventor
Toomas Neuman
Mehis Pold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CeMines Inc
Original Assignee
CeMines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CeMines Inc filed Critical CeMines Inc
Publication of AU2006216683A1 publication Critical patent/AU2006216683A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006216683A 2005-02-24 2006-02-24 Compositions and methods for classifying biological samples Abandoned AU2006216683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65685905P 2005-02-24 2005-02-24
US60/656,859 2005-02-24
PCT/US2006/006431 WO2006091734A2 (en) 2005-02-24 2006-02-24 Compositions and methods for classifying biological samples

Publications (1)

Publication Number Publication Date
AU2006216683A1 true AU2006216683A1 (en) 2006-08-31

Family

ID=36928007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006216683A Abandoned AU2006216683A1 (en) 2005-02-24 2006-02-24 Compositions and methods for classifying biological samples

Country Status (11)

Country Link
US (1) US20090075832A1 (cg-RX-API-DMAC7.html)
EP (1) EP1859266A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008532014A (cg-RX-API-DMAC7.html)
KR (1) KR20080003321A (cg-RX-API-DMAC7.html)
CN (1) CN101160524A (cg-RX-API-DMAC7.html)
AU (1) AU2006216683A1 (cg-RX-API-DMAC7.html)
CA (1) CA2598889A1 (cg-RX-API-DMAC7.html)
IL (1) IL185458A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007010349A (cg-RX-API-DMAC7.html)
RU (1) RU2007135030A (cg-RX-API-DMAC7.html)
WO (1) WO2006091734A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2201024A1 (en) * 2007-08-28 2010-06-30 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
TWI466680B (zh) * 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
GB0823366D0 (en) * 2008-12-22 2009-01-28 Uni I Oslo Synthesis
KR101067815B1 (ko) * 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
JP5823964B2 (ja) 2009-08-14 2015-11-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自閉症を診断及び治療する方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
EP2745115B1 (de) * 2011-08-19 2016-05-18 Protagen AG Neues verfahren zur diagnostik von hochaffinen bindern und markersequenzen
WO2013031757A1 (ja) * 2011-08-29 2013-03-07 東レ株式会社 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法
IN2014CN04690A (cg-RX-API-DMAC7.html) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc
US20130183242A1 (en) * 2012-01-18 2013-07-18 University Of Connecticut Methods for identifying tumor-specific polypeptides
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015172843A1 (en) * 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2015179469A2 (en) * 2014-05-20 2015-11-26 Kiromic, Llc Methods and compositions for treating malignancies with dendritic cells
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
AU2016281649B2 (en) * 2015-06-26 2022-08-04 The Regents Of The University Of California Antigenic peptides and uses thereof for diagnosing and treating autism
RS61062B1 (sr) 2015-07-16 2020-12-31 Inhibrx Inc Multivalentni i multispecifični dr5-vezujući fuzioni proteini
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3193173A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Serological autoantibodies as biomarker for colorectal cancer
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4035675A3 (en) * 2017-01-27 2022-11-16 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
EP3756680A1 (en) * 2019-06-26 2020-12-30 Universitat de Lleida Intermediate filament-derived peptides and their uses
WO2021011636A1 (en) * 2019-07-15 2021-01-21 Geisinger Health COMPOSITIONS AND METHODS OF TREATMENT FOR BREAST CANCER INVOLVING A NOVEL CAPERα-MLL1 COMPLEX
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法
CN111337678B (zh) * 2020-02-21 2023-06-06 杭州凯保罗生物科技有限公司 与肿瘤免疫治疗效果相关的生物标志物及其应用
CN116773798A (zh) * 2023-06-16 2023-09-19 北京三品医疗科技有限公司 多肽的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
AU2002226912A1 (en) * 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
WO2002073209A2 (de) * 2001-03-10 2002-09-19 Affina Immuntechnik Gmbh Verfahren zur identifikation von immunreaktiven epitopen auf proteinen
EP2302387A1 (en) * 2001-04-10 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles for insulin-dependent diabetes mellitus
EP1434860A2 (en) * 2001-09-28 2004-07-07 Incyte Genomics, Inc. Enzymes
EP1578970A1 (de) * 2002-12-23 2005-09-28 Hans-Jürgen Thiesen Human-autoantigene und deren verwendung
WO2004060302A2 (en) * 2002-12-26 2004-07-22 Cemines, Llc. Methods and compositions for the diagnosis, prognosis, and treatment of cancer

Also Published As

Publication number Publication date
WO2006091734A9 (en) 2006-10-19
CA2598889A1 (en) 2006-08-31
WO2006091734A3 (en) 2007-02-08
EP1859266A2 (en) 2007-11-28
CN101160524A (zh) 2008-04-09
RU2007135030A (ru) 2009-03-27
US20090075832A1 (en) 2009-03-19
IL185458A0 (en) 2008-01-06
JP2008532014A (ja) 2008-08-14
MX2007010349A (es) 2008-04-09
WO2006091734A2 (en) 2006-08-31
EP1859266A4 (en) 2010-07-28
KR20080003321A (ko) 2008-01-07

Similar Documents

Publication Publication Date Title
US20090075832A1 (en) Compositions and Methods for Classifying Biological Samples
M’Koma et al. Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine
EP1461423B1 (en) Antibody categorization based on binding characteristics
US20080081339A1 (en) Tumor associated markers in the diagnosis of prostate cancer
Lacombe et al. Use of autoantibodies to detect the onset of breast cancer
CN105917230B (zh) 用于确定胰腺癌的方法、阵列和其用途
AU2014204510B2 (en) Protein signature/markers for the detection of adrenocarcinoma
EP2951592A1 (en) Autoantibody signature for the early detection of ovarian cancer
WO2010108638A9 (en) Tumour gene profile
SG176962A1 (en) A method and system for the detection of cancer
WO2010115077A2 (en) Biomarker panels for barrett's esophagus and esophageal adenocarcinoma
JP2016519767A (ja) 前立腺がんに対するバイオマーカー検出における使用のための方法とアレイ
WO2015095136A1 (en) Immunosignature based diagnosis and characterization of canine lymphoma
JP2019526810A (ja) バイオマーカーサインおよびそれらの使用
WO2022207671A1 (en) Proteogenomic analysis of non-small cell lung cancer
Khattar et al. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer
CN113702636B (zh) 血浆自身抗体标志物在乳腺癌早期诊断及其分子亚型表征中的应用
HK1120108A (en) Compositions and methods for classifying biological samples
US20210080465A1 (en) SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR102839146B1 (ko) 류마티스 관절염 자가항체 레퍼토리의 프로파일링 및 그의 펩타이드 분류자
Forrester et al. An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays
WO2006071843A2 (en) Biomarkers for breast cancer
Dudas et al. Detecting tumor-specific autoantibodies for cancer diagnosis: a technology overview
Petros et al. IDENTIFICATION OF RACE-SPECIFIC BIOMARKERS FOR PROSTATE CANCER PROGRESSION FROM FORMALIN-FIXED BIOPSY TISSUE.: MP02-04

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application